AR062683A1 - Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos - Google Patents

Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos

Info

Publication number
AR062683A1
AR062683A1 ARP070103940A ARP070103940A AR062683A1 AR 062683 A1 AR062683 A1 AR 062683A1 AR P070103940 A ARP070103940 A AR P070103940A AR P070103940 A ARP070103940 A AR P070103940A AR 062683 A1 AR062683 A1 AR 062683A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydroxy
carboxylic acid
carboxy
och2
Prior art date
Application number
ARP070103940A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR062683A1 publication Critical patent/AR062683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de piridina, su preparacion y su uso, para la preparacion de medicamentos. Dichos compuestos actuan particularmente como agentes inmunomoduladores. Reivindicacion 1: Un compuesto de la Formula (1) en donde A representa *-CONH-CH2-, *-CO- CH=CH-, *-CO-CH2CH2-, grupo de formulas (2) donde los asteriscos indican el enlace donde ésta se une al grupo piridina de Formula 1; R1 representa C1-4-alquil, o cloro; R2 representa C1-5-alquil, C1-4-alcoxi, o C3-6-cicloalquil; R3 representa hidrogeno, C1-4-alquil, C1-4-alcoxi, o halogeno; R4 representa hidrogeno, C1-4-alquil, C1-4-alcoxi, halogeno, trifluormetil o trifluormetoxi; R5 representa 2,3-dihidroxipropil, di-(hidroxi-C1-4-alquil)-C1-4-alquil, -CH2-(CH2)kNHSO2R53, -(CH2)nCH(OH)- CH2-NHSO2R53, -CH2-(CH2)k-NHCOR54, -(CH2)nCH(OH)-CH2-NHCOR54, -CH2-(CH2)n-CONR51R52, -CO-NHR51, 1-(3-carboxi-azetidinil)-2-acetil, 1-(2-carboxi-pirrolidinil)-2-acetil, 1-(3-carboxi-pirrolidinil)-2-acetil, 1-(3-carboxi-azetidinil)-3-propionil, 1-(2- carboxi-pirrolidinil)-3-propionil, 1-(3-carboxi-pirrolidinil)-3-propionil, -(CH2)nCH(OH-CH2-NR51R52, hidroxi, hidroxi-C2-5-alcoxi, di-(hidroxi-C1-4-alquil)-C1-4-alcoxi, 2,3-dihidroxi-propoxi, 2-hidroxi-3-metoxi-propoxi, -OCH2-(CH2)m-NR51R52, 2- [(azetidina-3-ácido carboxílico)-1-il]-etoxi, 2-[(azetidina-3-ácido carboxílico C1-5-alquiléster)-1-il]-etoxi, 2-[(pirrolidina-3-ácido carboxílico)-1-il]-etoxi, 2-[(pirrolidina-3-ácido carboxílico C1-5-alquiléster)-1-il]-etoxi, -OCH2-CH(OH)-CH2- NR51R52, 3-[(azetidina-3-ácido carboxílico)-1-il]-2-hidroxipropoxi, 3-[(azetidina-3-ácido carboxílico C1-5-alquiléster)-1-il]-2-hidroxipropoxi, 2-hidroxi-3-[(pirrolidina-3-ácido carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(pirrolidina-3- ácido carboxílico C1-5-alquiléster)-1-il]propoxi, 2-hidroxi-3-[(pirrolidina-2- ácido carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(pirrolidina-2- ácido carboxílico C1-5-alquiléster)-1-il]-propoxi, -OCH2-(CH2)m-NHSO2R53, -OCH2-CH(OH)-CH2-NHSO2R53, -OCH2-(CH2)m- NHCOR54, -OCH2-CH(OH)-CH2-NHCOR54; R51 representa hidrogeno, C1-3-alquil, 2-hidroxietil, 2-hidroxi-1-hidroximetil-etil, 2,3-dihidroxipropil, carboximetil, 1-(C1-5-alquilcarboxi)metil, 2-carboxietil, o 2-(C1-5-alquilcarboxi)etil; R52 representa hidrogeno, metil, o etil; R53 representa C1-3-alquil, metilamino, etilamino, o dimetilamino; R54 representa hidroximetil, hidroxietil, aminometil, metilaminometil, dimetilaminometil, aminoetil, 2-metilaminoetil, o 2-dimetilamino-etil; k representa el numero entero 1, 2, o 3; m representa el numero entero 1 o 2; n representa 0, 1, o 2; y R6 representa hidrogeno, C1-4-alquil o halogeno, y una sal de tal compuesto.
ARP070103940A 2006-09-07 2007-09-06 Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos AR062683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006053147 2006-09-07

Publications (1)

Publication Number Publication Date
AR062683A1 true AR062683A1 (es) 2008-11-26

Family

ID=38983600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103940A AR062683A1 (es) 2006-09-07 2007-09-06 Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos

Country Status (27)

Country Link
US (1) US8580824B2 (es)
EP (1) EP2069336B1 (es)
JP (1) JP5253401B2 (es)
KR (1) KR101470659B1 (es)
CN (1) CN101511827B (es)
AR (1) AR062683A1 (es)
AU (1) AU2007292993B2 (es)
BR (1) BRPI0716171B8 (es)
CA (1) CA2661105C (es)
CL (1) CL2007002593A1 (es)
CY (1) CY1113727T1 (es)
DK (1) DK2069336T3 (es)
ES (1) ES2400533T3 (es)
HK (1) HK1133654A1 (es)
HR (1) HRP20130181T1 (es)
IL (1) IL197393A (es)
MA (1) MA30718B1 (es)
MX (1) MX2009002233A (es)
MY (1) MY149853A (es)
NO (1) NO342156B1 (es)
NZ (1) NZ576060A (es)
PL (1) PL2069336T3 (es)
PT (1) PT2069336E (es)
RU (1) RU2447071C2 (es)
SI (1) SI2069336T1 (es)
TW (1) TWI392671B (es)
WO (1) WO2008029371A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400163T3 (es) * 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
US7834039B2 (en) * 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
CA2679138C (en) * 2007-03-16 2015-05-26 Actelion Pharmaceuticals Ltd Amino-pyridine derivatives as s1p1/edg1 receptor agonists
EP2195311B1 (en) * 2007-08-17 2011-03-23 Actelion Pharmaceuticals Ltd. Pyridine derivatives as s1p1/edg1 receptor modulators
NZ585775A (en) * 2007-11-01 2011-12-22 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
CN101965345B (zh) * 2008-03-06 2014-05-28 埃科特莱茵药品有限公司 吡啶化合物
WO2009109907A1 (en) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
PL2252609T3 (pl) * 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące
AU2009220893A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
EP2278960B2 (en) 2008-03-17 2019-11-13 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
KR20210099206A (ko) 2008-07-23 2021-08-11 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
NZ591001A (en) 2008-08-27 2012-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
JP2012515788A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
EP2382211B1 (en) 2009-01-23 2012-12-19 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
JP5753104B2 (ja) * 2009-03-03 2015-07-22 メルク セローノ ソシエテ アノニム Ｓ１ｐ１レセプターアゴニストとして有用なオキサゾールピリジン誘導体
KR20120022757A (ko) * 2009-04-17 2012-03-12 이시하라 산교 가부시끼가이샤 2-할로게노-6위 치환-4-트리플루오로메틸피리딘의 제조 방법
DE102009002514A1 (de) * 2009-04-21 2010-10-28 Evonik Degussa Gmbh Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
ES2441845T3 (es) * 2009-07-16 2014-02-06 Actelion Pharmaceuticals Ltd. Derivados de piridin-4-ilo como agonistas de S1P1/EDG1
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
ES2548683T3 (es) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
US9187437B2 (en) 2010-09-24 2015-11-17 Bristol-Myers Squibb Company Substituted oxadiazole compounds
EP2665720B1 (en) * 2011-01-19 2015-06-10 Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl derivatives
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
ES2649475T3 (es) * 2013-03-15 2018-01-12 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
MX2017014846A (es) 2015-05-20 2018-02-19 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol.
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2017004609A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Thiadiazole modulators of s1p and methods of making and using
WO2017004608A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Oxadiazole modulators of s1p methods of making and using
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CN107311994A (zh) * 2017-08-14 2017-11-03 淄博职业学院 一种s1p‑1受体激动剂药物分子的新型合成方法
EA202091063A1 (ru) 2017-11-01 2020-09-18 Бристол-Маерс Сквибб Компани Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
ZA917371B (en) 1990-09-20 1992-06-24 Merrell Dow Pharma Calcium uptake inhibitors
DE4429465A1 (de) * 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
KR100875222B1 (ko) 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
ATE375340T1 (de) 2001-02-21 2007-10-15 Nps Pharma Inc Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) * 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CN1788008A (zh) 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
RU2390519C2 (ru) * 2003-08-29 2010-05-27 Оно Фармасьютикал Ко., Лтд. Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
KR20070045153A (ko) 2004-05-29 2007-05-02 7티엠 파마 에이/에스 의약용 씨알티에이치2 수용체 리간드
WO2006010379A1 (en) * 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
WO2006047195A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
ATE541830T1 (de) * 2004-12-13 2012-02-15 Ono Pharmaceutical Co Aminocarbonsäurederivat und dessen medizinische verwendung
KR20070116645A (ko) 2005-03-23 2007-12-10 액테리온 파마슈티칼 리미티드 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체
EP1863475B1 (en) * 2005-03-23 2011-09-07 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
MX2007011670A (es) * 2005-03-23 2007-11-15 Actelion Pharmaceuticals Ltd Derivados de benzo(c) tiofeno hidrogenados como inmunomoduladores.
AU2006232105A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
ATE477253T1 (de) 2005-04-26 2010-08-15 Neurosearch As Neuartige oxadiazol-derivate und deren medizinische verwendung
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
US20070043104A1 (en) * 2005-06-10 2007-02-22 Luthman Ingrid K UII-modulating compounds and their use
WO2006137019A1 (en) * 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
US20090054491A1 (en) 2005-06-28 2009-02-26 Astrazeneca Ab Use
AR057894A1 (es) * 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
CA2635124C (en) * 2006-01-24 2014-04-29 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
KR20080096780A (ko) 2006-02-21 2008-11-03 유니버시티 오브 버지니아 페이턴트 파운데이션 Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
UA91129C2 (ru) 2006-05-09 2010-06-25 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
AR061841A1 (es) * 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
ES2400163T3 (es) * 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
EP2081916A1 (en) 2006-09-29 2009-07-29 Novartis AG Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20080138955A1 (en) * 2006-12-12 2008-06-12 Zhiyuan Ye Formation of epitaxial layer containing silicon
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
CA2679138C (en) * 2007-03-16 2015-05-26 Actelion Pharmaceuticals Ltd Amino-pyridine derivatives as s1p1/edg1 receptor agonists
EP2195311B1 (en) * 2007-08-17 2011-03-23 Actelion Pharmaceuticals Ltd. Pyridine derivatives as s1p1/edg1 receptor modulators
NZ585775A (en) * 2007-11-01 2011-12-22 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
AU2008334297A1 (en) * 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of S1P1/EDG1
WO2009109907A1 (en) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
CN101965345B (zh) * 2008-03-06 2014-05-28 埃科特莱茵药品有限公司 吡啶化合物
PL2252609T3 (pl) * 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące
AU2009220893A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
EP3782991A1 (en) 2008-05-14 2021-02-24 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
ES2441845T3 (es) 2009-07-16 2014-02-06 Actelion Pharmaceuticals Ltd. Derivados de piridin-4-ilo como agonistas de S1P1/EDG1

Also Published As

Publication number Publication date
NO342156B1 (no) 2018-04-09
NZ576060A (en) 2011-11-25
US20100063108A1 (en) 2010-03-11
BRPI0716171A2 (pt) 2013-09-17
JP2010502695A (ja) 2010-01-28
TWI392671B (zh) 2013-04-11
PL2069336T3 (pl) 2013-05-31
AU2007292993A1 (en) 2008-03-13
CA2661105A1 (en) 2008-03-13
EP2069336B1 (en) 2012-12-26
BRPI0716171A8 (pt) 2017-12-26
IL197393A0 (en) 2009-12-24
TW200817357A (en) 2008-04-16
JP5253401B2 (ja) 2013-07-31
PT2069336E (pt) 2013-03-07
DK2069336T3 (da) 2013-02-25
BRPI0716171B1 (pt) 2021-05-11
CY1113727T1 (el) 2016-06-22
NO20091394L (no) 2009-04-06
HK1133654A1 (en) 2010-04-01
WO2008029371A1 (en) 2008-03-13
US8580824B2 (en) 2013-11-12
CL2007002593A1 (es) 2008-06-13
HRP20130181T1 (hr) 2013-03-31
IL197393A (en) 2013-09-30
SI2069336T1 (sl) 2013-03-29
MA30718B1 (fr) 2009-09-01
RU2009112538A (ru) 2010-10-20
BRPI0716171B8 (pt) 2021-05-25
ES2400533T3 (es) 2013-04-10
CN101511827A (zh) 2009-08-19
RU2447071C2 (ru) 2012-04-10
KR20090050102A (ko) 2009-05-19
CA2661105C (en) 2015-01-06
CN101511827B (zh) 2012-02-01
AU2007292993B2 (en) 2013-01-24
KR101470659B1 (ko) 2014-12-08
EP2069336A1 (en) 2009-06-17
MX2009002233A (es) 2009-03-16
MY149853A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
AR062683A1 (es) Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AR062684A1 (es) Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
ATE507212T1 (de) Morpholine als 5ht2c-agonisten
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR065621A1 (es) Derivados de amino-piridina, una composicion farmaceutica que los comprende y su uso como medicamento para el tratamiento de enfermedades asociadas al sistema inmune activado.
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
UA107324C2 (uk) Похідні 1,2,3-триазолу для застосування як інгібіторів стеароїл-coa десатурази
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR061134A1 (es) Derivados de tioxantina
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
MX2009003383A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones

Legal Events

Date Code Title Description
FG Grant, registration